Annovis Bio, Inc. (ANVS)

Annovis Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	6.24	9	6.06	3.59	0.83
Research & Development	38.79	16.52	8.48	3.05	0.78
Operating Expenses	45.04	25.51	14.54	6.64	1.61
Operating Income	-45.04	-25.51	-14.54	-6.64	-1.61
Interest Expense / Income	0	0	0	0	-0.04
Other Expense / Income	11.17	-0.18	-0.05	-1.18	-0.57
Pretax Income	-56.2	-25.33	-14.49	-5.46	-0.99
Net Income	-56.2	-25.33	-14.49	-5.46	-0.99
Shares Outstanding (Basic)	9	8	8	6	0
Shares Outstanding (Diluted)	9	8	8	6	0
Shares Change	10.55%	7.03%	20.88%	2132.36%	1.81%
EPS (Basic)	-6.23	-3.10	-1.90	-0.87	-3.51
EPS (Diluted)	-6.23	-3.10	-1.90	-0.87	-3.51
Free Cash Flow	-39.97	-17.31	-9.13	-3.97	-0.48
Free Cash Flow Per Share	-4.43	-2.12	-1.20	-0.63	-1.69
EBITDA	-56.2	-25.33	-14.49	-5.46	-1.03
EBIT	-56.2	-25.33	-14.49	-5.46	-1.03

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).